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Variation in Organ-Specific PIK3CA andKRASMutant
Levels in Normal Human Tissues Correlates With
Mutation Prevalence in Corresponding Carcinomas
Barbara L. Parsons,* Karen L. McKim, andMeagan B. Myers
Division of Genetic and Molecular Toxicology, U.S. Food and Drug
Administration, National Center for Toxicological Research, Jefferson, Arkansas
Large-scale sequencing efforts have described
the mutational complexity of individual cancers
and identified mutations prevalent in different
cancers. As a complementary approach, allele-
specific competitive blocker PCR (ACB-PCR) is
being used to quantify levels of hotspot cancer
driver mutations (CDMs) with high sensitivity, to
elucidate the tissue-specific properties of CDMs,
their occurrence as tumor cell subpopulations,
and their occurrence in normal tissues. Here we
report measurements of PIK3CA H1047R mutant
fraction (MF) in normal colonic mucosa, normal
lung, colonic adenomas, colonic adenocarcino-
mas, and lung adenocarcinomas. We report
PIK3CA E545K MF measurements in those tis-
sues, as well as in normal breast, normal thy-
roid, mammary ductal carcinomas, and
papillary thyroid carcinomas. We report KRAS
G12D and G12V MF measurements in normal
colon. These MF measurements were integrated
with previously published ACB-PCR data on
KRAS G12D, KRAS G12V, and PIK3CA
H1047R. Analysis of these data revealed a
correlation between the degree of interindividual
variability in these mutations (as log10 MF stan-
dard deviation) in normal tissues and the fre-
quencies with which the mutations are detected
in carcinomas of the corresponding organs in
the COSMIC database. This novel observation
has important implications. It suggests that inter-
individual variability in mutation levels of nor-
mal tissues may be used as a metric to identify
mutations with critical early roles in tissue-
specific carcinogenesis. Additionally, it raises
the possibility that personalized cancer thera-
peutics, developed to target specifically
activated oncogenic products, might be repur-
posed as prophylactic therapies to reduce the
accumulation of cells carrying CDMs and,
thereby, reduce future cancer risk. Environ. Mol.
Mutagen. 58:466–476, 2017. VC 2017 This arti-
cle is a U.S. Government work and is in the public domain
in the USA. Environmental and Molecular Mutagenesis pub-
lished by Wiley Periodicals, Inc. on behalf of Environmental
Mutagen Society
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INTRODUCTION
Large-scale cancer genome sequencing projects have
been valuable in terms of identifying the prevalent cancer
driver mutations (CDMs) associated with particular types
of cancers [Ciriello et al., 2013; Kandoth et al., 2013;
Watson et al., 2013; Stover and Wagle, 2015]. Cancer
“drivers” have been defined as genetic events associated
with tumor initiation or progression [Alizadeh et al.,
2015] and as somatic mutations that increase the fitness
of a cell [Fisher et al., 2013]. More broadly, a cancer
driver is “a cell autonomous or non-cell autonomous
alteration that contributes to the tumor evolution at any
stage—including initiation, progression, metastasis, and
resistance to therapy—by promoting a variety of func-
tions including proliferation, survival, invasion, or
immune evasion” [Alizadeh et al., 2015]. Some of the
most impactful cancer drivers are hotspot point mutations.
Hotspot point mutations merit investigation because of
their high prevalence in cancer, their established roles as
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early events in carcinogenesis, and evidence that the
mutant proteins can be therapeutic targets and/or determi-
nants of the efficacy of specific anticancer therapies (i.e.,
biomarkers to inform personalized approaches to cancer
treatment) [Lu et al., 2014; Ryan et al., 2015]. There are
known hotspot base substitution mutations in the PIK3CA
and KRAS genes. The prevalence of these mutations in
carcinomas of the breast, colon, lung and thyroid are pro-
vided in Supporting Information Table S1 (data from Cat-
alogue of Somatic Mutations in Cancer, COSMIC)
[COSMIC, 2016].
Individual tumors are heterogeneous in terms of histol-
ogy, genetics, epigenetics, phenotypic markers, and gene
expression [Bonavia et al., 2011; Marusyk et al., 2012]. It
has been established that cancers exhibit spatial and tem-
poral genetic diversity, meaning different mutations have
been detected in different sectors of a cancer and that
abundance of clonal subpopulations can evolve over time
[Martelotto et al., 2014; Renovanz and Kim, 2014]. Inves-
tigations into the genetic heterogeneity of several cancers
has enabled clinicians to identify patients who will benefit
from particular therapies (i.e., personalized cancer treat-
ment) and, conversely, demonstrated that mutant cell sub-
populations can derail the process and drive the
development of acquired resistance to therapy [Fisher
et al., 2013; Burrell and Swanton, 2014; Stover and
Wagle, 2015]. Given the extent of tumor heterogeneity,
the prevalence of mutant subpopulations in advanced can-
cers and the difficulties associated with treating such can-
cers, it has been suggested that the development of cancer
preventative modalities may be a more effective approach
for reducing cancer deaths [Maresso et al., 2015].
Because tumor heterogeneity is a consequence and a
reflection of the mechanisms driving tumor initiation and
progression, understanding the origins of tumor heteroge-
neity is critical for designing therapeutic strategies to
block the development of resistance to treatment [Hiley
et al., 2014]. In addition, information about the earliest
stages of carcinogenesis is needed as a foundation for
experimental approaches to abrogate or delay the devel-
opment of cancer [Kensler et al., 2016]. For these rea-
sons, there is growing interest in describing the mutations
present in normal and pre-neoplastic tissues and tracking
genetic changes during tumor progression and treatment
[Hiley et al., 2014; Jamal-Hanjani et al., 2014; Nakamura
et al., 2014; Roberts and Gordenin, 2014; Francioli et al.,
2015; Martincorena and Campbell, 2015].
It has been asserted that a majority of cancers (65%,
with 95% CI of 39–81%) arise due to spontaneous muta-
tions, a claim based on the correlation between the inci-
dence of cancer in different tissue types and the number
of stem cell divisions in those tissues [Tomasetti and
Vogelstein, 2015]. Others have claimed that intrinsic fac-
tors account for <10 to 30% of lifetime cancer risk and
“rates of endogenous mutation accumulation due to
intrinsic processes are not sufficient to account for the
observed cancer rates” [Wu et al., 2016]. Clearly, addi-
tional information about the frequencies of spontaneous
mutations in cancer driver genes and the selective advan-
tages they may confer is necessary to clarify how sponta-
neous mutations contribute to cancer risk and whether
reducing spontaneous CDM frequencies through medical
intervention is a viable approach for reducing cancer
deaths [Martincorena and Campbell, 2015].
Our laboratory uses a high sensitivity method called
Allele-specific Competitive Blocker PCR (ACB-PCR), to
quantify specific CDMs in normal and cancerous tissue
samples derived from particular organs [Parsons et al.,
2010; Myers et al., 2014a, 2015, 2016]. By comparing
ACB-PCR amplification of unknown samples to that of a
standard curve, ACB-PCR can determine the ratio of muta-
nt:wild-type sequence in a DNA sample, measuring one
specific base substitution mutation at a time, as long as the
mutant to wild-type ratio is 1025. The ACB-PCR limit
of detection is considered to be 1 3 1025 because this is
the lowest MF standard that can be discriminated experi-
mentally from a wild-type only control. An ACB-PCR MF
of 1025 equates to the detection of three mutant molecules
in a total of 300,000. ACB-PCR is robust in the measure-
ment of MFs between 1021 and 1025 (ACB-PCR may
underestimate MFs between 1021 and 1). ACB-PCR can
identify robustly which samples have MFs below 1025, but
cannot measure MFs below 1025. This sensitivity is
unlikely to be sufficient to detect neutral mutations in nor-
mal human tissues. For some CDMs, however, this sensi-
tivity has been shown to be sufficient for the mutant
quantification in normal rodent and human tissues, likely
due to clonal expansion of cells carrying CDMs that confer
a positive selective advantage [Parsons et al., 2005, 2010,
2012; McKinzie et al., 2006; Meng et al., 2010a,b 2011;
McKinzie and Parsons, 2011; Banda et al., 2013, 2015].
Information about ultralow frequency mutant cell popula-
tions can complement existing characterizations of tumor
samples by next-generation sequencing (NGS, which gen-
erally detects variant alleles only at frequencies >1% [Cot-
trell et al., 2014]), to yield a more complete description of
the genetic changes present in cancers. Here we report
quantification of levels of the PIK3CA E545K and
H1047R hotspot point mutations in normal colonic
mucosa, colonic adenocarcinomas, normal lung, and lung
adenocarcinomas, as well as levels of the PIK3CA E545K
mutation in normal breast, mammary ductal carcinoma,
normal thyroid, and papillary thyroid carcinoma (PTC).
These mutations were selected because they have the
potential to provide a positive selective advantage. The
PIK3CA E545K (guanine to adenine mutation at codon
545) results in a glutamine to lysine amino acid change in
the p110a kinase binding domain. The PIK3CA H1047R
(adenine to guanine mutation at codon 1047) results in a
histidine to arginine amino acid change in the p110a
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kinase binding domain. Both PIK3CA mutations increase
activation of PI3K and its binding to the cell membrane,
thereby impacting oncogenic transformation, cell prolifera-
tion, cell growth, survival, differentiation and altering inva-
sion potential [Myers et al., 2016].
KRAS is a downstream mediator of growth factor
receptor signaling, with critical roles in cell proliferation,
survival, and differentiation. The KRAS G12D (GGT to
GAT at codon 12 resulting in a glycine to aspartic acid
amino acid change) and KRAS G12V (GGT to GTT at
codon 12 resulting in a glycine to valine amino acid
change) mutations alter the phenotype of KRAS, provid-
ing a context-dependent selective advantage [Parsons and
Myers, 2013]. Here, we also report additional measure-
ments of KRAS G12D and G12V in normal colonic
mucosa. These new data, integrated with that published
previously, creates a dataset of four hotspot point muta-
tions (KRAS G12D, KRAS G12V, PIK3CA E545K, and
PIK3CA H1047R) in normal and malignant tissues from
four different organs. Analysis of these data demonstrates
that interindividual variability in cancer driver gene
mutant fraction (MF) within normal tissues is correlated
with the tissue-specific prevalence of carcinomas carrying
the corresponding mutations.
MATERIALS ANDMETHODS
Sample Collection
Procedures for the acquisition and analysis of anonymous human tis-
sues were reviewed by the FDA’s IRB (Research Involving Human Sub-
jects Committee, FWA 00006196). The National Disease Research
Interchange (NDRI, Philadelphia, PA) and the National Cancer Insti-
tute’s Cooperative Human Tissue Network (CHTN) were identified as
the primary sources of normal and malignant tissues, respectively.
Fresh-frozen, normal breast, normal colonic mucosa, normal lung, and
normal thyroid tissue samples, as well as one fresh-frozen papillary thy-
roid carcinoma (PTC), were purchased from the NDRI [Parsons et al.,
2010; Myers et al., 2014a, 2015, 2016]. Fresh-frozen, primary breast
ductal carcinomas (DCs), colonic adenomas, colonic adenocarcinomas,
lung adenocarcinomas, and PTCs, along with normal colonic mucosa
samples, were provided by the CHTN [Parsons et al., 2010; Parsons and
Myers 2013; Myers et al., 2014a, 2015, 2016]. These samples were col-
lected at autopsy from tissue donors (one sample per donor) who died
from causes unrelated to cancer or diseases affecting the relevant target
organ. The numbers of samples analyzed for the different mutations are
given in Supporting Information Table S2. All tumor specimens were
histologically evaluated and classifications were confirmed by board cer-
tified pathologists. The extent of information provided regarding the
smoking history of the subjects was inconsistent across subjects (and in
some instances absent), only allowing for stratification of subjects as
ever- and never-smokers.
DNA Isolation and First-Round PCR
DNA isolation was performed as described previously [Parsons et al.,
2010; Myers et al., 2014a, 2015, 2016], using sufficient tissue to ensure that
the characteristic cellular content of each tissue type would be represented
proportionally in the genomic DNA. The average weights of the tissue sam-
ples processed for breast, colonic mucosa (separated from submucosa), lung
and thyroid were 4.0, 0.4, 2.3, and 1.9 g, respectively. A high fidelity, first-
round PCR amplification of a 306 bp sequence encompassing human
PIK3CA codon 545 was performed for each DNA sample, using 1 mg of
EcoRI-digested genomic DNA in a 200 ll PCR reaction mix of: 10 mM
KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.75), 2 mM MgSO4, 0.1%
Triton X-100, 0.1 mg/ml bovine serum albumin, 0.2 mM dNTPs, and 10
units of cloned PfuUltra Hotstart DNA Polymerase (Agilent Technologies,
Santa Clara, CA). The primers were 5’-GGGAAAATGACAAAGAACAG-
3’ and 5’-AATGTGCCAACTACCAATGT-3’. The thermocycler reaction
conditions were 2 min at 948C, followed by 31 cycles of 1 min at 948C, 2
min at 568C, and 1 min at 728C, followed by a final 7 min at 728C exten-
sion and 48C hold.
A high fidelity, first-round PCR amplification of a 265 bp sequence encom-
passing human PIK3CA codon 1047 was performed for each DNA sample,
using 1 mg of EcoRI-digested genomic DNA in a 200 ll PCR reaction mix of:
10 mM KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.75), 2 mM MgSO4,
0.1% Triton X-100, 0.1 mg/ml bovine serum albumin, 0.2 mM dNTPs, and 10
units of cloned PfuUltra Hotstart DNA Polymerase (Agilent Technologies).
The primers were 5’-CCAAACTGTTCTTATTACTTATAG-3’ and 5’-
GAAGATCCAATCCATTTTTGT-3’. Thermocycler reaction conditions were
2 min at 948C, followed by 33 cycles of 1 min at 948C, 1 min at 528C, and 1
min at 728C, followed by a final 6 min at 728C extension and 48C hold.
The high fidelity, first-round PCR of a 384 bp sequence encompass-
ing human KRAS codon 12 was described previously [Myers et al.,
2014a]. Each first-round PCR employed one intron-specific primer to
avoid amplification of pseudogenes.
Synthesis of PIK3CA andKRASWTandMutant Standards
Plasmids carrying the mutant or wild-type sequences (for the two dif-
ferent amplicons of the PIK3CA gene) were used as template to synthe-
size mutant and wild-type standards. Plasmids carrying G12D mutant
KRAS, G12V mutant KRAS, and wild-type KRAS sequences were used
as template to synthesize standards. Each of the standards was synthe-
sized using conditions identical to those used to amplify the unknown
genomic DNAs, except that the amount of input plasmid DNA was cali-
brated prior to PCR to ensure approximately equivalent amplification in
the synthesis of standards and unknowns.
Purification and Quantification of Standards and
Unknowns
Purification of PIK3CA E545K WT, mutant, and unknown PCR prod-
ucts was accomplished by ion-pair reverse phase chromatography using
non-denaturing conditions and a Transgenomic WAVE Nucleic Acid
Fragment Analysis and Collection system (Omaha, NE). PIK3CA
H1047R PCR products and KRAS PCR products were gel purified as
described previously [Myers et al., 2016]. The DNA concentration of
each sample was determined using an Epoch Spectrophotometer Model
(Biotek, Winooski, VT), calculated as the average of three measurements
that varied by 10% from the group mean.
ACB-PCR
Mutant (either PIK3CA E545K, PIK3CA H1047R, KRAS G12D, or
KRAS G12V) and WT reference DNA samples were mixed to generate
standards with mutant:WT ratios (i.e., MFs) of 1021, 1022, 1023, 1024,
1025, and 0 (containing only the WT sequence), at a concentration of 5
3 107 copies/ll for the PIK3CA E545K mutation or 1 3 108 copies/ml
for the PIK3CA H1047R mutation. Each ACB-PCR reaction employed
10 ll of each DNA mixture, for a total of 5 3 108 or 1 3 109 copies
per reaction for the E545K and H1047R assays, respectively. Each MF
standard was analyzed in duplicate, along with a no-DNA control. ACB-
PCR reactions were performed in 96-well PCR plates (Thermo Fisher
Scientific, Waltham, MA) using three primers: a fluorescein-labeled
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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mutant-specific primer (MSP), a non-extendable blocker primer (BP, to
reduce background amplification of WT PIK3CA), and an upstream/
downstream primer [Myers et al., 2014b]. The ACB-PCR measurement
of KRAS G12D and G12V was performed as described previously
[Myers et al., 2015].
For PIK3CA E545K mutation, each 50 ml ACB-PCR reaction contained:
13 Universal Taq Buffer [New England BioLabs, Inc. (NEB), Beverly, MA),
1.5 mM MgCl2, 0.1 mg/ml gelatin, 1.0 mg/ml Triton X-100, 80 mM dNTPs,
400 nM each primer [MSP, 5’-fluorescein-TCCTCTCTCTGAAATCACCA-
3’; BP, 5’-TCCTCTCTCTGAAATCACCdG’3’ (i.e., 3’-deoxyG modifica-
tion); and downstream primer, 5’-CAGAGAATCTCCATTTTAGC-3’], 3 ng/
ml ET SSB (NEB), 2.8 mU/ml Perfect Match PCR Enhancer (Stratagene, La
Jolla, CA), and 0.08 ml Hemo KlenTaq DNA polymerase (NEB). Cycling
conditions were 2 min at 948C, followed by 36 cycles of 948C for 30 sec,
418C for 90 sec, and 688C for 1 min. The PIK3CA E545K ACB-PCR product
is 77 bp in length.
For PIK3CA H1047R mutation, each 50 ml ACB-PCR reaction contained:
13 Universal Taq Buffer, 0.75 mM MgCl2, 0.1 mg/ml gelatin, 1.0 mg/ml
Triton X-100, 40 mM dNTPs, 270 nM MSP (5’-fluorescein-
TGTTGTCCAGCCACCATGTC-3’), 500 nM BP (5’-TGTTGTCCAGC-
CACCATGTdT-3’), 1.5 mM downstream primer (5’-GATGCTTGGCTCTG-
GAATGC-3’), 1.2 mU/ml Perfect Match PCR Enhancer, and 0.3 ml Hemo
KlenTaq DNA polymerase. Cycling conditions were 2 min at 948C, fol-
lowed by 41 cycles of 948C for 30 sec, 498C for 45 sec, and 728C for 1
min. The PIK3CA H1047R ACB-PCR product is 148 bp in length. Blocker
primers were purchased from Sigma Genosys (The Woodlands, TX),
all others were purchased from Integrated DNA Technologies, Inc. (Coral-
ville, IA).
Vertical Polyacrylamide Gel Electrophoresis, Image
Analysis, and Data Collection
Following ACB-PCR, 10 ml of 63 ficoll loading buffer/dye were
added to each 50 ml reaction, and 10 ml of each ACB-PCR product were
analyzed on 8% nondenaturing, polyacrylamide gels. A PharosFX
Molecular Imager with an external blue laser (Bio-Rad) was used to
visualize the fluorescent ACB-PCR products. Quantity One software
(Bio-Rad), with a locally averaged background correction, was used to
quantify the pixel intensities of the correct-sized bands. For the PIK3CA
E545K, log-log plots relating MF to fluorescence were constructed and
fit with a power function. For the PIK3CA H1047R, KRAS G12D, and
G12V mutations, log-linear plots relating MF to fluorescence were con-
structed and fit with a logarithmic function. Using the function of the
standard curve and the pixel intensities of the ACB-PCR products, the
MF (ratio of mutant to wild-type sequence) of each unknown sample
was calculated.
Statistical Analyses
For each sample, MF was calculated as the arithmetic average of
three independent ACB-PCR measurements. The average MF measure-
ment for each sample was log10-transformed. For each mutational target,
the geometric mean MF was calculated as the average log10-transformed
MF measured for a particular tissue type. Statistical analyses were per-
formed using log10-transformed data.
Log-transformed datasets were examined for normality using the
D’Agostino and Pearson omnibus normality test. Nonparametric
approaches were applied to log-transformed data that were not normally
distributed. The Mann-Whitney rank sum test was used when a quantita-
tive ranking of MFs was possible. Contingency analyses were used to
test for statistical significance when datasets contained multiple samples
with MFs below the limit of accurate ACB-PCR quantification (i.e.,
<1025). Specifically, the numbers of samples with MFs >1025 and
<1025 were examined using v2 or Fisher’s exact test. Pearson correla-
tion analyses were performed on log-transformed, normally-distributed
data (Spearman’s rank correlation analyses were performed when data
were not normally-distributed). Two-tailed P values <0.05 were consid-
ered significant. All statistical analyses were performed using GraphPad
Prism 5 Software (GraphPad Software, Inc., La Jolla, CA).
RESULTS
The goals of this study were to elucidate the role of
spontaneous CDMs in tissue-specific carcinogenesis and
to define the prevalence of low frequency CDMs within
cancers. Therefore, unlike many studies that examine
tumor tissue and normal tumor adjacent sample, this
study examined the levels of hotspot CDM in “normal”
autopsy samples from men (except breast) and women
without cancer or disease in the relevant organ.
Levels of PIK3CA E545K mutation (codon 545
GAG!AAG) were measured in normal breast, colonic
mucosa, lung, and thyroid DNA samples, as well as in
DNA isolated from ductal carcinomas, colonic adenomas,
colonic adenocarcinomas, lung adenocarcinomas, and
papillary thyroid carcinomas. Each unknown was quanti-
fied in three independent experiments, generating a data-
set of 441 PIK3CA E545K MF measurements. The
numbers of samples analyzed for each tissue type are pre-
sented in Supporting Information Table S2. Following
ACB-PCR, products were run on vertical polyacrylamide
gels. Replicate examples of PIK3CA E545K ACB-PCR
output are provided in Supporting Information Figure S1.
MF quantification was achieved by interpolation of the
fluorescent intensities of unknown samples with that of a
standard curve constructed using samples with defined
ratios of mutant:WT alleles (i.e., duplicate 1021, 1022,
1023, 1024, 1025, and 0 standards). A representative
example of a PIK3CA E545K ACB-PCR standard curve
is shown in Supporting Information Figure S2. The aver-
age coefficient of determination (r2) for the PIK3CA
E545K standard curves were as follows: breast, 0.9730
(range 0.9662–0.9828); colon, 0.9628 (range 0.9334–
0.9831); lung, 0.9595 (range 0.9316–0.9726); and thyroid,
0.9670 (range 0.9595–0.9724). The measured MFs are
given in Supporting Information Table S3. The average
coefficient of variation for the triplicate PIK3CA E545K
MF measurements obtained from individual breast, colon,
lung, and thyroid samples were 0.36, 0.55, 0.35, and
0.43, respectively.
PIK3CA H1047R (codon 1047 CAT!CGT) MF was
measured in normal colonic mucosa and lung DNA sam-
ples, as well as in DNA isolated from colonic adenomas,
colonic adenocarcinomas, and lung adenocarcinomas (see
Supporting Information Table S2). Each unknown was
quantified in three independent experiments (276 PIK3CA
H1047R MF measurements). Replicate examples of
PIK3CA H1047R ACB-PCR output are provided in Sup-
porting Information Figure S1. A representative example
of a PIK3CA H1047R ACB-PCR standard curve is shown
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in Supporting Information Figure S2. The average coeffi-
cient of determination (r2) for the standard curves used to
measure PIK3CA H1047R MF in colon and lung were
0.9849 (range 0.9732–0.9928) and 0.9802 (range 0.9738–
0.9840), respectively. The PIK3CA H1047R MFs are
given in Supporting Information Table S4. The average
coefficient of variation for the triplicate PIK3CA H1047R
MF measurements obtained from individual colon and
lung samples were 0.40 and 0.16, respectively.
Fifteen normal colonic mucosa samples were analyzed
for KRAS G12D (codon 12 GGT!GAT) and G12V
(codon 12 GGT!GTT) MFs as described above (90
ACB-PCR MF measurements), adding to the previously
published ACB-PCR analysis of six colonic mucosa sam-
ples [Parsons et al., 2010]. Replicate examples of the
KRAS G12D and G12V ACB-PCR output are provided in
Supporting Information Figure S1. Representative exam-
ples of KRAS G12D and G12V standard curves are shown
in Supporting Information Figure S2. The average coeffi-
cient of determination (r2) for the standard curves used to
measure KRAS G12D and G12V MF in colon were
0.9895 (range 0.9735–0.9969) and 0.9889 (range 0.9744–
0.9973), respectively. The KRAS G12D and G12V MFs
are given in Supporting Information Table S5. The aver-
age coefficient of variation for the triplicate KRAS G12D
and G12V MF measurements obtained from individual
colon samples were 0.52 and 0.17, respectively.
Comparison of PIK3CA E545K, PIK3CA H1047R,KRAS
G12D, andKRAS G12VMFs Between Normal and
Malignant Tissues
A summary of MF measurements for normal tissues
and tumors is given in Table I. No significant differences
were observed between the levels of PIK3CA E545K
mutation in normal tissues and tumor samples, for any of
the organs examined (see Fig. 1), although the increased
MFs in colonic adenomas compared to normal colonic
mucosa were of borderline significance (Fisher’s exact
test, P5 0.0741). No significant differences were
observed between the levels of PIK3CA H1047R mutation
in normal tissue and tumors of the colon or lung (see Fig.
1). For KRAS G12D and G12V, the 15 ACB-PCR meas-
urements from normal colonic mucosa were compared to
those previously published for colonic adenomas and
adenocarcinomas [Parsons et al., 2010]. This analysis
confirmed an earlier report conducted using just six nor-
mal samples. Significant differences in MF were observed
among sample types (Kruskal-Wallis test, P 5 0.0013),
with colonic adenomas having significantly greater KRAS
G12D mutant levels than normal colonic mucosa. Signifi-
cant differences in KRAS G12V MFs were also observed
(v2 test, P 5 0.0220).
The data developed in the current study, combined
with that previously published [Parsons et al., 2010;
Myers et al., 2014a, 2015, 2016], constitutes a data set of
more than 1,800 ACB-PCR MF measurements on 606
different DNA samples. The mutant frequency distribu-
tions observed in normal/tumor tissue pairs are presented
in Figure 1, for each mutation analyzed. Figure 1 illus-
trates for the first time: (1) the tissue-specific differences
in ultralow frequency KRAS and PIK3CA mutation levels,
(2) the remarkable prevalence of low-frequency mutant
populations, and (3) in some cases, a suprising overlap in
the frequency distributions between normal and tumor.
MFMeasurements in Normal Tissues
PIK3CA H1047R MF in normal colonic mucosa and
lung, along with PIK3CA E545K MF in normal colonic
TABLE I. Summary of ACB-PCR MF Measurements
Sample type Gene mutation Tissue Median MF Geomean MF
No. samples
>1025
No. samples
<1025
Mutation positive
samples (%)
Normal PIK3CA H1047R Colon 1.57 3 1025 1.98 3 1025 20 0 100
PIK3CA H1047R Lung 2.45 3 1025 3.96 3 1025 19 0 100
PIK3CA E545K Breast 6.06 3 1026 1.78 3 1025 4 6 40
PIK3CA E545K Colon 2.67 3 1026 2.69 3 1026 0 20 0
PIK3CA E545K Lung 5.35 3 1026 6.75 3 1026 3 16 16
PIK3CA E545K Thyroid 6.52 3 1026 7.02 3 1026 5 14 26
KRAS G12D Colon 2.88 3 1025 4.90 3 1025 15 0 100
KRAS G12V Colon 7.66 3 1026 1.08 3 1025 6 9 40
Adenoma PIK3CA H1047R Colon 1.73 3 1025 4.56 3 1025 8 1 89
PIK3CA E545K Colon 2.15 3 1026 2.38 3 1026 2 6 25
Carcinoma PIK3CA H1047R Colon 1.63 3 1025 3.46 3 1025 19 1 95
PIK3CA H1047R Lung 2.54 3 1025 3.48 3 1025 24 0 100
PIK3CA E545K Breast 3.92 3 1025 8.36 3 1025 7 2 78
PIK3CA E545K Colon 3.07 3 1026 7.89 3 1026 3 17 15
PIK3CA E545K Lung 4.17 3 1026 7.13 3 1026 4 20 8
PIK3CA E545K Thyroid 8.39 3 1026 8.78 3 1026 7 11 39
The median and geomean MFs shown in italics are below the limit of accurate ACB-PCR quantification (1025).
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mucosa, lung, breast, and thyroid, were examined for cor-
relations with age, smoking status, and gender. No statis-
tically significant associations with age or smoking status
were observed (comparing ever smoker vs. never-smok-
ers). For colonic mucosa, however, the PIK3CA H1047R
mutation was significantly more abundant in DNA from
men than from women (Fig. 2). This novel finding is con-
sistent with the higher age-adjusted incidence rates for
colorectal cancer among men than among women
[Abotchie et al., 2012]. In addition, KRAS G12D MF in
normal colonic mucosa was positively correlated with
age, although this correlation was statistically significant
at only the 90% confidence level (Spearman r5 0.4553,
P 5 0.0576).
Table I and Figure 3 show there are differences in
mutation prevalence and variability across normal tissue
types. For example, all colonic mucosa samples had
PIK3CA H1047R and KRAS G12D MFs >1025, whereas
none of the normal colonic mucosa DNA samples had
PIK3CA E545K MFs >1025. MF measurements in nor-
mal tissues were analyzed statistically for tissue-specific
differences (see Table I and Fig. 3). Because many
PIK3CA E545K mutations were below the limit of accu-
rate ACB-PCR quantification (1025), statistical
differences between normal tissue types were examined
using a v2 test (comparing the numbers of samples with
MFs greater than and less than 1025 across tissues). This
analysis detected a significant difference in levels of
PIK3CA E545K mutation across the normal tissue types
(P 5 0.0328). Current PIK3CA H1047R MF measure-
ments in normal tissues were combined with those pub-
lished previously. Because all PIK3CA H1047R MFs
were >1025, analysis of variance was performed using a
Fig.1. The frequency distributions are shown for PIK3CA E545K, PIK3CA H1047R, KRAS G12D, and KRAS G12V in
paired datasets of normal and malignant tissues. The data presented include that reported in the current publication, inte-
grated with that reported previously [Parsons et al., 2010; Parsons and Myers, 2013; Myers et al., 2014a, 2015, 2016].
Measurements within the shaded area of the graph are below the lowest MF standard used and are considered below the
limit of accurate ACB-PCR quantification.
Fig. 2. Significantly greater PIK3CA H1047R MFs were observed in
DNA samples isolated from normal male colonic mucosa as compared to
normal female colonic mucosa. The asterisk denotes statistical signfi-
cance, Mann Whitney test, P 5 0.0068.
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Kruskal-Wallis test, with a Dunn’s Multiple Comparison
post-test. This analysis identified significant differences in
PIK3CA H1047R MF across tissue types (P 5 0.0001),
and established that PIK3CA H1047R MFs in breast
DNA samples were significantly greater than those of
DNA from colonic mucosa.
This dataset was used to investigate relationships
between tissue-specific MF measurements and the impor-
tance of particular mutations in tissue-specific carcinogen-
esis. Frequencies of the PIK3CA E545K, PIK3CA
H1047R, KRAS G12D, and KRAS G12V mutations in car-
cinomas of the breast, large intestine, lung, and thyroid
were collected from the expertly curated data in the COS-
MIC database (v76) [COSMIC, 2016] (see Supporting
Information Table S1). We determined that the log10 geo-
mean MFs from the 16 sets of ACB-PCR MF measure-
ments collected from normal tissues (PIK3CA E545K,
PIK3CA H1047R, KRAS G12D, and KRAS G12V in
breast, colonic mucosa, lung, and thyroid) were not corre-
lated with the frequencies with which these mutations are
reported in carcinomas from each organ (Spearman
r5 0.3676, P 5 0.1612).
Visual inspection of the data, however, suggested that
mutations reported to occur frequently in particular cancers
showed large inter-individual variability in the ACB-PCR
MFs in normal tissues (e.g., PIK3CA H1047R for breast,
KRAS G12D for colon, see Figs. 1 and 3) [COSMIC,
2016]. Therefore, the relationship between interindividual
variability (as log10 MF standard deviation) and the fre-
quency of mutation within the various target organs was
examined. Calculated MFs were used, except when the cal-
culated MFs were below the theoretical limit of detection
3.33 3 1026 (a log10 MF of 25.477), which is equivalent
to one mutant molecule in a background of 3 3 105 WT
molecules. In order to standardize the analysis of standard
deviation across the data set and avoid overestimation of
MF standard deviation due to non-detects, samples with a
MF below 3.33 3 1026 were ascribed a MF of 3.00 3
1026 (log10 MF 25.481, less than 1 mutant molecule per
300,000). The non-detects included 2/10 breast PIK3CA
E545K measurements, 13/20 colon PIK3CA E545K meas-
urements, 3/19 lung PIK3CA E545K measurements, 1 thy-
roid PIK3CA E454K measurement, and 1 breast KRAS
G12D measurement. A strong correlation was observed
between the log10 MF standard deviation and the frequen-
cies of the mutations in carcinomas from the corresponding
organs (Spearman r5 0.7265, P5 0.0014). The correlation
was significant with and without the correction for non-
detects, but the correlation was stronger with the correction
[Spearman r (without correction)5 0.6382, P 5 0.0078].
Furthermore, the correlation was not driven by a single
data point. Even when the breast PIK3CA H1047R data
point (log10 MF standard deviation5 1.2418; COSMIC
tumor prevalence5 13.5%) was removed from the
Fig. 3. Variability in CDM frequency is tissue- and mutant target-specific. Individual ACB-PCR measurements were
plotted for four different mutations (PIK3CA E545K, PIK3CA H1047R, KRAS G12D, and KRAS G12D) in normal DNA
samples isolated from four different tissues (breast, colonic mucosa, lung, and thyroid). Measurements within the shaded
area of the graph are below the lowest MF standard used and are considered below the limit of accurate ACB-PCR
quantification.
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analysis, a strong correlation was observed (r5 0.6679,
P 5 0.0065). The log10 MF variance within normal tissue
samples also correlated significantly with the frequency of
mutations in tumors of the cognate target organ (Spearman
r5 0.5088, P 5 0.0441). In Figure 4, linear regression
analysis was used to depict the relationship between log10
MF standard deviation in normal tissue and the correspond-
ing prevalence by tumor type for the mutations examined.
DISCUSSION
The PIK3CA and KRAS mutations analyzed in this
study are recognized hotspot point mutations, meaning
they are overrepresented in tumor sequence databases
compared to most other mutations. For example, the
PIK3CA H1047R mutation is the most prevalent somatic
mutation detected in DCs. KRAS G12D is the most preva-
lent somatic mutation detected in colonic adenocarcino-
mas. Beyond that, the signaling dysfunctions caused by
the mutant proteins are well-described. Thus, these muta-
tions are functional drivers of carcinogenesis.
Mutations within these genes are even more prevalent
in tumors than previously appreciated, when the mutation
detection method employed is capable of detecting muta-
tions within low-frequency mutant cell subpopulations
(see Supporting Information, Table S6). The current study
demonstrates PIK3CA mutant cells are prevalent as sub-
populations within colon adenomas, colon adenocarcino-
mas, and lung adenocarcinomas. Further, some breast
DCs carry subpopulations of PIK3CA E545K mutant
cells, as well as previously reported subpopulations of
PIK3CA H1047R [Myers et al., 2016].
We conclude that these particular mutations are able to
impact tumor initiation and progression as relatively small
subpopulations of cells. An early driver mutation, in a
tumor-initiating clone, is expected to result in a predomi-
nant mutation (variant allele frequency of 10–50%).
Such events would be detected by DNA sequencing and
account for the percentages of tumors reported in the
COSMIC database (Supporting Information Table S6).
The low variant allele frequencies (1025 to 1022),
detected in significant fractions of the tumors analyzed,
could arise in a number of different ways. First, the muta-
tion could occur late in tumor development. Second, the
mutation could occur in an initiating clone, whose growth
is outpaced by a cooperating initiating clone or clones.
Or, third, the mutation might confer a selective advantage
early, but not late in tumor progression. Because these
mutations are not sufficient for carcinogenesis, each of
these potential paths is expected to be impacted by the
accumulation of additional mutations in the tumor mass
as a whole.
There is growing evidence that tumors (including
breast and colon tumors) can have polyclonal or multian-
cestral architecture [Parsons, 2008; Zahm et al., 2016].
We propose that some mutations are able to function as
“transdriver” mutations, meaning small subpopulations of
cells can contribute to (or drive) the initiation and pro-
gression of a different clone (or clones) of cells, which
carry complementing genetic or epigenetic lesions. Such
clonal interactions have been documented [Inda et al.,
2010, 2011; Marusyk et al., 2014; Altrock et al., 2015]
and are believed to operate through paracrine or non-cell-
autonomous mechanisms [Hobor et al., 2012]. In a por-
tion of such cases of multiclonal initiation, a PIK3CA or
KRAS mutant cell may acquire an additional genetic hit
and progress to become the predominant tumor clone.
The alternative pathway is that the co-initiating clone(s)
acquire additional genetic or epigenetic damage and pro-
gress to become the predominant tumor clone(s), generat-
ing carcinomas with PIK3CA or KRAS mutant
subpopulations.
ACB-PCR quantification of PIK3CA and KRAS muta-
tions demonstrated there is a remarkable amount of interin-
dividual variability in the levels of these mutations in some
normal tissue types (most notably PIK3CA mutations in
breast and KRAS mutations in colon). Importantly, we
report for the first time a significant correlation exists
between the degree of interindividual variability in
PIK3CA and KRAS MFs in normal tissues and the tissue-
specific prevalence of the mutations in carcinomas. Con-
versely, the log10 geomean MF did not correlate with the
corresponding tumor mutation frequency. Because standard
deviation is influenced by the magnitude of the measured
variable, the variability among individuals samples com-
bined with the magnitude of the tissue-specific normal MF
measurements may be contributing to the observed correla-
tion (Fig. 4). These observations suggest that some level of
mutagenesis (an ACB-PCR measureable background MF)
Fig. 4. Correlation between the log10 MF standard deviation for PIK3CA
and KRAS hotspot point mutations in normal tissues and the frequencies
with which the mutations occur in corresponding carcinomas (breast duc-
tal carcinomas, colonic adenocarcinomas, lung adenocarcinomas, and pap-
illary thyroid carcinomas) according to the COSMIC database (v76)
[COSMIC, 2016]. Calculated MFs were used, except when calculated
MFs were below the theoretical limit of detection 3.33 3 1026 (log10
MF525.477, or one mutant molecule in a background of 3 3 105 WT
molecules).
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combined with tissue-specific clonal expansion (inter-sam-
ple variability in MF measurements) are characteristics of
cancer driver mutations within a particular tissue type.
These observations have important implications in terms of
establishing the relative importance of different mutations
as biomarkers of susceptibility for particular human tissues.
Further, this suggests that interindividual variation in MF
in normal tissues can be used as a metric to assess the
context-dependent, selective advantage of cells carrying
oncogenic point mutations.
According to Rozhok and DiGrigori, “oncogenic muta-
tions should have vastly different fitness effects on
somatic cells dependent on the tissue microenvironment
in an age-dependent manner” [Rozhok and DeGregori,
2015]. ACB-PCR MF measurements provide evidence
that PIK3CA and KRAS mutations impact mutant cell fit-
ness in a manner that is context dependent. In the current
study, we observed significant differences in PIK3CA
E545K and H1047R mutation abundance across the dif-
ferent normal tissue types. We also observed a gender
difference in PIK3CA H1047R MF in colonic mucosa.
The significantly greater levels of PIK3CA H1047R muta-
tion in male versus female colonic mucosa are consistent
with men having a greater risk of developing colon can-
cer than women. PIK3CA H1047R mutation increases in
abundance with age in normal breast, suggesting it con-
fers a positive selective advantage in breast [Myers et al.,
2016]. KRAS G12D and G12V mutations are more abun-
dant in colonic adenomas, as compared to normal colonic
mucosa, suggesting these mutations confer a selective
advantage early in carcinogenesis. However, there is a
significant decrease in KRAS G12V during adenoma to
adenocarcinoma progression (see Fig. 1) [Parsons et al.,
2010], and there is a significant inverse correlation
between KRAS G12V MF and maximum tumor dimension
for colon tumors and papillary thyroid carcinomas [Par-
sons and Myers, 2013], but not for lung adenocarcinomas
[Myers et al., 2015]. These data suggest that KRAS G12V
is neutral or selected against in some large/advanced can-
cers. This negative selection in large/advanced cancers
could explain the prevalence of pre-existing KRAS mutant
tumor cell subpopulations in the colorectal cancers that
develop resistance to anti-EGFR monoclonal antibody
therapy [Diaz et al., 2012; Misale et al., 2012].
There are a few reports of KRAS mutations being
detected in normal colon and lung tissues [Ronai et al.,
1994; Yakubovskaya et al., 1995; Sudo et al., 2006; Par-
sons et al., 2010]. Recently, Gao et al. [2017] reported
detecting KRAS mutations in 52/156 histologically normal
bronchial biopsies from former lung cancer patients. To
our knowledge, there is only one report of PIK3CA muta-
tion in normal tissue (breast) [Myers et al., 2016],
although PIK3CA mutations have been detected in breast
hyperplasia [COSMIC, 2016] and ductal hyperplasia with
columnar cell change [Ang et al., 2012]. Data from the
current and previous ACB-PCR analyses [Parsons et al.,
2010; Myers et al., 2014a, 2015, 2016], allow us to con-
clude that cells carrying PIK3CA and KRAS hotspot point
mutations are prevalent in normal tissues. The prevalence
of PIK3CA and KRAS mutations in normal tissues is con-
sistent with the mathematically-derived conclusion that
“half or more of the somatic mutations in cancers of self-
renewing tissues originate prior to tumor initiation”
[Tomasetti et al., 2013, 2017].
There is an ongoing debate about the degree to which
spontaneous mutation determines human cancer risk.
Recent publications by Tomasetti and Vogelstein high-
light the importance of spontaneous mutation in tissue-
specific carcinogenesis [Tomasetti et al., 2013]; they sug-
gest that two-thirds of cancers are attributable to random
mutations in normal stem cells due to replication errors
[Tomasetti and Vogelstein, 2015; Tomasetti et al., 2017].
Others contend that “cancer risk is heavily influenced by
extrinsic factors,” with only 10 to 30% of cancers due to
intrinsic factors [Wu et al., 2016]. Our results refute argu-
ments that spontaneous mutation is insufficiently frequent
to have an impact on carcinogenesis, as the combination
of spontaneous mutation plus subsequent cell selection
must give rise to the relatively high levels of mutations
that we observed in normal tissues.
The concept of hotspot transdriver mutations has the
potential to unify the opposing schools of thought regard-
ing the importance of intrinsic versus extrinsic factors in
carcinogenesis. Spontaneous transdriver mutations can be
viewed as substrates that contribute to carcinogenesis,
potentially though interaction with exogenously-induced
genetic or epigenetic changes. Our analysis does not dis-
criminate spontaneous from exogenously-induced muta-
tion. Given the deficits in the smoking histories for the
normal tissue samples, the lack of significant associations
between MF and smoking history should be interpreted
cautiously and revisited in the future. Nevertheless, given
the relative insensitivity of epidemiological studies and
the relatively small sample sizes analyzed by ACB-PCR,
it seems unlikely that the significant correlation we
observed between inter-individual variability in cancer
driver MF and tissue-specific prevalence of the corre-
sponding mutations in carcinomas is due solely to exoge-
nous exposures. That said, the correlation depicted in
Figure 4 may provide some insights into which cancers
are impacted by exogenous exposures. The three data
points where the cancer incidence is greater than the lin-
ear regression expectation correspond to PIK3CA E545K,
KRAS G12D, and KRAS G12V in colorectal cancer, a
cancer whose incidence is considered to have an extrinsic
exposure component.
The remarkable prevalence of PIK3CA and KRAS
mutations in DNA from normal tissues suggests that there
may be significant opportunities for cancer prevention.
Therapies that target pre-existing oncomutations in
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normal tissues have the potential to decrease future can-
cer risk. Progress is being made in developing therapeu-
tics that target mutant KRAS [Patricelli et al., 2016].
Therapies that target mutant KRAS or PIK3CA proteins
could also be investigated as prophylactic therapies in
individuals with Noonan and Cowden syndromes, who
have high cancer risk because they carry germline muta-
tions in these genes.
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